<DOC>
	<DOCNO>NCT00423189</DOCNO>
	<brief_summary>The PDT/Lucentis trial Phase IV comparative trial comparing use combination therapy ITV ranibizumab verteporfin PDT ITV ranibizumab alone patient exudative AMD .</brief_summary>
	<brief_title>Lucentis Utilizing Visudyne ( LUV Trial ) Combination Therapy Treatment Age-Related Macular Degeneration</brief_title>
	<detailed_description>The PDT/Lucentis trial Phase IV comparative trial comparing use combination therapy ITV ranibizumab verteporfin PDT ITV ranibizumab alone patient exudative AMD . Patients randomize one three group . All patient receive three consecutive monthly treatment ITV ranibizumab . Patients randomize group I receive ITV ranibizumab . Patients randomize group II also receive one treatment reduce fluence ( 20 % fluence ) verteporfin PDT day 0 . Patients randomize group III also receive one treatment reduce fluence ( 40 % fluence ) vPDT . All patient also evaluate possible retreatment ranibizumab accord establish criterion . Thirty patient ( ten per group ) recruit one U.S. sit 6-month period . Randomization occur time entry study . Follow-up continue month 12 ( day 0 ) subject .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<mesh_term>Verteporfin</mesh_term>
	<criteria>Ability provide write informed consent comply study assessment full duration study Age &gt; 55 year Subfoveal neovascular membrane confirm fluorescein angiography ICG Visual acuity well 20/32 bad 20/320 ETDRS refraction Any previous vitrectomy study eye ( posterior anterior associate vitreous loss cataract surgery ) Intracapsular cataract extraction ( posterior capsule need present ) Previous treatment ranibizumab Previous treatment pegaptanib Previous treatment ITV triamcinolone Any previous treatment photodynamic therapy Previous history retinal detachment study eye Any previous radiation treatment head/ neck Significant cardiovascular disease cancer would prevent followup visit completion 12 month study Prior enrollment study AMD study eye Participation another simultaneous medical investigator trial Ocular disorder study eye may confound interpretation study result , include retinal detachment macular hole . Concurrent disease study eye could compromise visual acuity require medical surgical intervention study period Aphakia absence posterior capsule study eye Previous violation posterior capsule also exclude unless occur result YAG laser posterior capsulotomy association prior , posterior chamber intraocular lens implantation History idiopathic autoimmune uveitis either eye Significant structural damage center macula study eye likely preclude improvement visual acuity follow resolution macular edema , include atrophy retinal pigment epithelium , subretinal fibrosis , laser scar ( ) Vitreomacular traction epiretinal membrane study eye evident biomicroscopically OCT Ocular inflammation ( include trace ) study eye Uncontrolled glaucoma ( defined intraocular pressure ≥30 mm Hg despite treatment anti medication ) previous filtration surgery study eye Infectious blepharitis , keratitis , scleritis , conjunctivitis ( either eye ) current treatment serious systemic infection Spherical equivalent refractive error study eye 8 diopter myopia ( For patient refractive cataract surgery study eye , preoperative spherical equivalent refractive error 8 diopter myopia allow ) Systemic Conditions Uncontrolled Blood pressure exceed diastolic pressure 100 mm Hg ( sit ) screen period Uncontrolled diabetes mellitus Renal failure require dialysis renal transplant Premenopausal woman use adequate contraception Previous participation study investigational drug ( exclude vitamin mineral ) within 3 month precede Day 0 History disease , metabolic dysfunction , physical examination finding , finding give reasonable suspicion disease condition contraindicate use investigational drug , might affect interpretation result study , render subject high risk treatment complication INR ≥ 3.0 ( e.g . due current treatment warfarin ) . The use aspirin exclusion . Other History allergy fluorescein , amenable treatment History allergy shellfish History allergy intravenous iodine History allergy indocyanine green Inability obtain fundus photographs angiogram sufficient quality analyze graded central reading center Inability comply study follow procedure History allergy humanize antibody component ranibizumab formulation</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>LUV</keyword>
	<keyword>Lucentis</keyword>
	<keyword>Visudyne</keyword>
	<keyword>PDT</keyword>
	<keyword>AMD</keyword>
	<keyword>ARMD</keyword>
	<keyword>Age</keyword>
	<keyword>Related</keyword>
	<keyword>Macular</keyword>
	<keyword>Degeneration</keyword>
</DOC>